Raymond James reiterates Strong Buy on Relay Therapeutics stock

Novartis proposed acquisition includes a $2.0B upfront payment and up to $1.0B in milestones for SNV4818, setting a valuation floor for Relay Therapeutics’ zovegalisib. Relay shares have surged 208% over the past year, trade at $9.95 with a $1.78B market cap and ~ $1.2B enterprise value, yet M&A comps (4–6x forward sales) imply a $3.5B–$4.0B valuation. Multiple analysts reiterated/raised targets (Raymond James $19, Oppenheimer $14, Guggenheim $22, Citizens $15) after Phase 1/2 data showing an 11.1-month PFS and FDA Breakthrough Therapy designation. The deal and trial readouts materially boost Relay’s M&A/strategic optionality and sector valuation comparables.

Analysis

The recent deal flow in early-stage PI3Kα and adjacent oncology assets materially re-prices acquisition optionality for mid-cap developers, raising the probability that an asset with a coherent Phase 3 plan and combo data will trade at a substantial premium to standalone biotech multiples. That increases negotiating leverage for management teams that can credibly de-risk tolerability and demonstrate additive benefit with standard-of-care CDK4/6 inhibitors, and it makes buyout timing a key optionality rather than a binary clinical outcome.

Second-order winners include CROs and CDMOs with capacity to quickly scale combination-therapy biomarker testing and commercial formulation supply; payers and specialty pharmacies are the eventual chokepoints, as any premium pricing will be met with pathway negotiations and utilization management that can cut realized sales by 20–40% versus headline incidence if evidence for broader-line use is thin. Conversely, companies with single-arm data but unclear comparator benefit are at risk of being valued as niche post-line therapies rather than franchise-creating drugs, compressing multiples.

Key catalysts and risks cluster on a tight 6–18 month horizon: upcoming combo and Phase 3 gating readouts will determine whether the market awards a sustained M&A premium or reverts to binary clinical valuation. Tail risks include class-wide safety signals, payor pushback that materially reduces price realization, or a competing asset showing superior tolerability—each can erase the acquisition premium quickly and drive substantial downside for equity holders.

From a positioning perspective, the base-case is asymmetric upside from continued deal appetite but concentrated binary downside around pivotal data and commercialization assumptions. The consensus appears to place too much weight on comparables and too little on payer dynamics and execution complexity, so structures that capture takeover optionality while capping clinical downside are preferable.

Key Decisions for Investors

• RLAY — Buy a defined-cost directional: purchase a 9–12 month call spread roughly 25–50% OTM (size: 1–2% of liquid long-biotech sleeve). Rationale: captures M&A upside and positive Phase 2/3 combo readouts with capped premium loss; target 2.5x–4x return if a takeout or strong readout occurs, max loss = premium paid.
• RLAY — Equity + protection: go long a modest equity position (1–3% NAV) and buy 6–12 month puts ~20–30% OTM for downside protection. Rationale: maintains upside participation for takeover narrative while limiting drawdown risk from a negative clinical surprise; cost of protection is the insurance premium.
• Event-pair: Long RLAY / Short a small-cap oncology basket (equal-dollar) lacking near-term Phase 3 catalysts (re-balance monthly). Rationale: isolates idiosyncratic clinical/M&A upside while hedging sector moves; expected payoff if RLAY captures acquisition premium while peers do not.
• SMCI — Governance-driven short or buy puts (1–2% NAV, short-tenor 3 months): treat as tactical volatility trade tied to reputational and execution risk. Rationale: asymmetric downside from legal/governance events and likely elevated volatility; tight stop-loss and small sizing to limit event-reversal risk.